HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearchCompany Lookup
The Week

'Biopharma ecosystem is back to full health,' fueled by M&A: PwC

With pharma and life sciences deal values surpassing $65 billion in the first quarter, marking the strongest quarter in the industry since 2020, analysts from PwC have declared that the "biopharma ecosystem is back to full health."

By FiercePharma · Jun 17, 2026 · via FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Daiichi Sankyo flags accounting error, as shares tank despite revenue beat
A Daiichi Sankyo quarterly report that should have celebrated strong commercial execution was instead derailed…
Aug 1, 2026
The WeekFierceBiotech ↗
Chutes & Ladders-Legend CEO departs without successor in place
Legend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was…
Aug 1, 2026
FDA Expands Pluvicto Into Earlier PSMA-Positive Metastatic Prostate Cancer
The WeekBriefing
FDA Expands Pluvicto Into Earlier PSMA-Positive Metastatic Prostate Cancer
Novartis’ Pluvicto won FDA approval on July 31 for use with ARPI therapy in PSMA-positive metastatic androgen …
Aug 1, 2026